STX-0712

N/A

Report date: 2025/04/22 15:33:33

Base Information

Drug NameSTX-0712
Drug Alias NameSTX-0712
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-C-C chemokine receptor type 2Antibody-dependent cell-mediated cytotoxicity (ADCC) effects
TargetsC-C chemokine receptor type 2
Therapy Area/IndicationsLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesSolu Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesSolu Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A